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Hepatitis E virus (HEV) is a leading cause of acute icteric hepatitis and acute liver failure in the 
developing world. During the last decade, there has been increasing recognition of autochthonous – 
or locally acquired- HEV infection in developed countries. Chronic HEV infection is now recognised, 
and in transplant recipients this may lead to cirrhosis and organ failure.  
Aim 
To detail current understanding of the molecular biology of HEV, diagnostic and therapeutic strategies 
and propose future directions for basic science and clinical research.  
Methods 
PubMed was searched for English language articles using the key words ‘hepatitis E’, ‘viral hepatitis’, 
‘autochthonous infection’, ‘antiviral therapy’, ‘liver transplantation’, ‘acute’, ‘chronic’, ‘HEV’, ‘genotype’, 
‘transmission’ ‘food-borne’, ‘transfusion’. Additional relevant publications were identified from article 
reference lists.  
Results 
There has been increasing recognition of autochthonous HEV infection in Western countries, mainly 
associated with genotype 3. Chronic HEV infection has been recognised since 2008, and in transplant 
recipients this may lead to cirrhosis and organ failure. Modes of transmission include food-borne 
transmission, transfusion of blood products and solid organ transplantation. Ribavirin therapy is used 
to treat patients with chronic HEV infection, but new therapies are required as there have been 
reports of treatment failure with ribavirin. 
Conclusions 
Autochthonous HEV infection is a clinical issue with increasing burden. Future work should focus on 
increasing awareness of HEV infection in the developed world, emphasising the need for clinicians to 
have a low threshold for HEV testing, particularly in immunosuppressed patients. Patients at potential 




Hepatitis E (HEV) was initially identified in the late 1970s as an epidemic non-A non-B hepatitis that 
caused an infectious waterborne illness similar to hepatitis A
1
. Now, HEV is a leading cause of icteric 
hepatitis and acute liver failure in the developing world. Worldwide, the estimated annual incidence of 
HEV infection is 20 million, resulting in around 56,600 deaths
2
. Predominantly, infections are 
recognised as occurring in developing countries as large epidemics due to poor sanitation and are 
mainly associated with what are known as genotypes 1 and 2.  In this instance, pregnant individuals 
are more susceptible to severe infection, and often develop a more aggressive clinical course 
associated with a poor outcome (3000 stillbirths annually are reportedly caused by HEV
3
). Over the 
course of the last decade, there has been increasing recognition of autochthonous (locally acquired) 
HEV infection in Western countries, mainly associated with genotype 3
4, 5
. Worldwide endemicity for 
HEV (all genotypes) is detailed in Figure 1
6
. Furthermore, chronic HEV infection has been recognised 
since 2008
7




In this review we detail current understanding of the molecular biology of HEV, clinical relevance of 
genotypic HEV infection, diagnostic and therapeutic strategies and propose future directions for basic 
science and clinical research.  
 
METHODS 
A systematic search was performed using the PubMed electronic database for relevant English 
language abstracts and full text articles published between 1990 and January 2017. Manual review of 
the reference lists of selected full text articles was also undertaken to identify additional eligible 
articles. The search terms included: ‘hepatitis E’, ‘viral hepatitis’, ‘autochthonous infection’, ‘antiviral 
therapy’, ‘liver transplantation’, ‘acute’, ‘chronic’, ‘HEV’, ‘genotype’, ‘transmission’ ‘food borne’, 
‘transfusion’ and ‘ribavirin’.  
 
THE MOLECULAR BIOLOGY OF HEPATITIS E VIRUS  
HEV is a small (27-34mm) single-stranded RNA virus
9
, approximately 7.2kb in length with 7 currently 
recognised genotypes
10
. It is known to be non-enveloped in bile and faeces, and is present in blood, 
coated in a lipid membrane. HEV consists of a 5’ short non-coding region (NCR), ORF1 (which 
encodes the non-structural proteins), ORF3 (which encodes a small multifunctional protein), ORF2 
(which encodes the capsid protein) and a 3’NCR followed by a polyadenosine tail approximately 150-
200 bases long (Figure 2). A novel fourth open reading frame (ORF4) has been identified, situated 
within the ORF1 region of the HEV genome, encoding a 20kDa (139-158aa long) protein during 
endoplasmic reticulum stress which interacts with host and viral proteins to control the activity of the 
viral RNA dependent RNA polymerase
11
. However, ORF4 is unique to, although universal amongst, 
genotype 1 HEV strains. 
ORF1 and ORF2/3 are separated by a junction region (JR), whereas ORF2 and ORF3 overlap and 
are transcribed as a bicistronic subgenomic mRNA
12
. The genome contains 2 cis-reactive elements 
(CREs), one in the JR and one overlapping the 3’ end of ORF2 and the 3’NCR
13, 14
. The sequence 
and stem loop structure of the CRE in the JR is essential for replication and may also serve as the 
promoter for the subgenomic region
12
.  The 3’NCR CRE localises the RNA-dependent RNA 
polymerase
15
. The 5’ end of both the genomic and subgenomic RNA is capped
16
. A 76 nucleotide 
region in the 5’NCR is responsible for binding the ORF2 protein and is considered to play a role in 
viral assembly
17
.  The coding region of ORF1 begins immediately after the 5’NCR and extends over 
5082 nucleotides. ORF1 encodes a 1693 amino acid polyprotein with a molecular mass of 
approximately 186kDa and several putative functional domains (Figure 2) including; a 
methyltransferase (MT) domain for 5’ capping, a Y domain of unknown function, a papain-like 
cysteine protease (PCP) domain, a proline rich region that contains a hypervariable region, a X 
domain of unknown function, a helicase (Hel) domain, and a RNA dependent RNA polymerase 
(RdRp)
18
. However, the protease activity of the PCP domain is a subject of some debate, with some 
reports suggesting that this domain may instead de-ubiquinate proteins, preventing the prosomal 
degradation of protein required for viral replication
19
. The capsid protein of HEV is expressed by 
ORF2. The ORF2 protein contains 4 domains; the N terminals, arginine rich, shell, middle and 
protruding domain. Neutralizing antibodies have been shown to bind to the P and M domains, 
suggesting that these play a role in cell binding and entry
20
. Studies involving the expression of a 
truncated form of ORF2 by a baculovirus expression system in insect cells have produced HEV like 
particles
21
. Such virus like particles have been shown to bind to heparan sulfate proteoglycans 
(HSPGs) and HSPG expression on the cell surface is required for in vitro infection
22
. ORF3 encodes a 
small 114 amino acid protein approximately 13kDa in size. The ORF3 protein is believed to interact 
with several cell proteins to facilitate HEV replication, for example; interacts with hemopexin (affecting 
iron homeostasis), binds to SH3 domain containing proteins (which function in the signal transduction 
pathway and promote cell survival) and interacts with Tsg101 and α1-microglobulin to facilitate the 
sorting of the endosomal sorting complexes required for transport (ESCRT)
23, 24, 25)
. However, ORF3 
protein’s key role is believed to be in viral assembly and egress, with phosphorylated ORF3 
interacting with the capsid protein
26
. Interestingly monoclonal antibodies to ORF3 were able to bind 
nascent virions but not faecal virions
27
. Further studies indicated that virions circulating in human 
serum banded at a lower sucrose gradient in comparison to faecally derived virions and were not 
neutralized by the presence of antibodies in cell culture systems in the way faecally derived virions 




Negative sense intermediate replicates are detected during replication and attachment receptors have 
been identified but overall, the viral life cycle of HEV has not been extensively studied
29,30
. This is, in 
part, due to the slow progress in the development of reliable culture methods for HEV. Similarly, in 
vivo studies have been hampered due to the absence of a small animal model, until recently; with 
three studies achieving viral inoculation of human liver chimeric mice with HEV
31, 32, 33
. Interestingly, 
these reports indicated greater success using genotype 1 strains as inoculants (in contrast to in vitro 
studies) and all achieved greater infection and viraemia rates in inoculated mice using faecally 
derived HEV virions, in comparison to serum or culture derived. Two studies examined the use of 
ribavirin in inoculated chimeric mice and demonstrated the treatment to be successful in reducing 
viraemia in therapeutics
31, 33
. However, ribavirin induced anaemia was common in the treated mice (a 
side effect documented in humans)
31. 
   
 
HEV Phylogeny 
All HEV strains belong to the family Hepeviridae, which has not been assigned to any order. The 
family Hepeviridae contains 2 genera; Piscihepevirus and Orthohepevirus. Piscihepevirus contains 
one species; piscihepevirus A, which contains all known cutthroat trout strains of hepatitis E. The 
Orthohepevirus genus contains 4 species; orthohepevirus A, orthohepevirus B, orthohepevirus C and 
orthohepevirus D.  All avian strains are contained in the species orthohepevirus B. The strains 
isolated from humans and pigs are all assigned to orthohepevirus A, as are the strains which infect 
camels, deer, rabbits, mongooses and some rat strains. Orthohepevirus C contains all strains isolated 




HEV has 7 known genotypes; genotypes 1-4 and 7 displaying human tropism
35
. Whilst genotypes 1 
and 2 infect only humans, genotype 3 and 4 strains have been isolated from various animals and 
genotype 7 strains have been isolated from camels
36
. HEV appears to be unique amongst human 
hepatitis viruses, as recombination events appear to alter the replicative capacity, tissue specificity 




Genotypes 1 and 2 
Genotypes 1 and 2 are endemic in developing countries, where they cause water-borne outbreaks. 
These are obligate human pathogens, transmitted via the faeco-oral route and clinical presentation 
with genotype 1 or 2 infection is indistinguishable from any other cause of acute viral hepatitis.  
 
Genotypes 3 and 4 
The most common mode of HEV transmission in developed countries is believed to be food-borne 
zoonosis
38
. Evidence of HEV as a zoonosis first came from the detection of HEV in pigs with a high 
homology to HEV strains found in humans
39
. Since then many potential animal reservoirs for HEV 
have been identified
40
. Only genotypes 3 and 4 of the species orthohepevirus A, and genotype 7, are 
recognised as zoonotic and circulate mainly in developed countries
40
. Host species for genotypes 3 
and 4 include pigs, deer, rabbits, mongoose, cattle, sheep and horses 
(39, 41. 42; 43; 44; 45).
 Food-borne 
zoonosis of HEV has been documented in several case reports, and undercooked or raw pork has 
now been identified as a significant risk factor for human HEV infection. Transmission via 
contaminated shellfish
46
 and soft fruits
47
 is also recognised as a potential source of food-borne 




To date, only one incidence of genotype 7 infection in humans has been documented; this was a case 
of a liver transplant recipient in the United Arab Emirates who regularly consumed camel milk and 
meat
48
. However, the incidence of camelid HEV in humans in countries with large camel populations 
deserves further attention.  
 
Importantly, the virus can present as two quite distinct clinical conditions: large epidemics in endemic 
areas (genotype 1 in Africa and Asia, genotype 2 in Mexico and Africa: sporadic cases are recognised 
but less common than epidemics) and isolated cases amongst asymptomatic individuals in developed 
countries (genotype 3 and 4). HEV is a virus with ‘two faces’, behaving in a remarkable contrast 
between developing and developed countries and according to genotype
49 
(Table 1).  
 
GENOTYPE 1 AND 2 HEV INFECTION 
Epidemiology – Figure 1 
Genotype 1 and 2 cause a waterborne, epidemic hepatitis with the virus being transmitted via the 
faeco-oral route. Recent and novel work using human liver chimeric mice as a model of HEV infection 
demonstrated that HEV genotype 1 infection was established after intravenous injection of stool 
derived HEV virions, whereas intraperitoneal or intravenous injection of HEV-positive patient serum 
did not lead to active HEV infection
33
. This finding suggests that at least for HEV genotype 1, stool 
derived HEV virions are more infectious than virions derived from serum. HEV genotypes 1 and 2 are 
endemic in developing countries; HEV genotype 1 is a common cause of acute hepatitis in Asia (in 
particular India), whereas genotype 2 is prevalent in Central America, Mexico and Africa. These 
genotypes are restricted to humans.  
The World Health Organization estimates that there are 20 million HEV infections worldwide, leading 
to an estimated 3.3 million symptomatic cases of HEV
50
, and 56,600 HEV related deaths
2
. However, 
this estimate was based on data from only 9 out of 21 of the Global Disease Burden areas worldwide, 
and it is likely that the true burden of disease is much higher. The majority of these infections are 
genotype 1 and 2, affecting patients in the developing world; imported cases are also observed in 
developed countries. Case fatality rates in epidemics range from 0.2 to 4%
49
. However, mortality rates 




 Hepatitis E infection and Pregnancy 
HEV infection during pregnancy (particularly during the third trimester) leads to a worsening in both 
maternal and foetal outcomes compared with other acute viral hepatitides, however the pathogenesis 
of HEV infection in pregnant females, and the resultant high mortality rate, is incompletely 
understood. The high mortality rate is likely to be a result of a number of complex and interacting 
factors, including viral, host, hormonal and immunological factors. Potential important contributing 
factors include high viral load
52
, dysregulation of the progesterone receptor signalling pathway and 
other hormonal changes in pregnancy
53
. In pregnant women with genotype 1 HEV infection, a 
significantly higher viral load is seen in patients with acute liver failure compared with acute hepatitis, 
and higher viral loads were observed in patients with foetal death compared with patients without 
foetal death
52
. Defective monocyte-macrophage function occurs in pregnant patients with HEV-
induced acute liver failure compared with HEV-induced acute liver injury, with reduced toll-like 
receptor 3 and toll-like receptor 7 expression and concomitant reduction in toll-like receptor 
downstream signalling
54
. This suggests an inadequate trigger for the innate immune response 
contributes to the development and severity of HEV-induced acute liver failure in pregnancy. 
Pregnancy is associated with a high level of steroid hormones, which may promote viral replication 
and suppress CD4 cells
55
. HEV-infected women with acute liver failure have lower CD4 counts and 
higher CD8 counts. Pregnant women with HEV acute liver failure have also been shown to have 
higher levels of oestrogen, progesterone and B-HCG compared with HEV negative patients or control 
healthy pregnant women
55
. The role of herbal medicines has also been debated, with one group 
suggesting that HEV-infected pregnant women may be more likely to take herbal medicines, which 
could also contribute to the high mortality in certain geographical regions
56
. 
In addition, in Central Asia and eastern Africa, high mortality rates have also been reported amongst 
HEV infected children aged under 2 years
57,58
.   
 
Clinical Features 
The majority of acute HEV infections are asymptomatic; if present (in 20% of those with genotype 1 or 
2 HEV infection)
3
, symptoms are often non-specific and include anorexia, nausea, fatigue, myalgia 
and jaundice. Laboratory tests show elevated serum bilirubin levels and a marked rise in liver 
enzymes. The mean incubation period is 40 days (range 15-60 days). Most acute infections resolve 
spontaneously, with symptoms disappearing within 4-6 weeks. However, acute HEV infection can 
cause acute liver failure, most commonly in pregnant females in the developing world as described 
above. Whereas acute HEV infection can cause severe acute liver injury in the Western world, it 
rarely causes acute liver failure. Genotype 1 and 2 infections have also been implicated in the 
development of acute on chronic liver failure/decompensated liver disease. In countries where HEV is 
endemic, the number of cases of acute on chronic liver failure secondary to HEV is variable (ranging 
from 4% to 75%) with a median short term mortality rate of 34% (range 0% - 100%)
59
. One study from 
India reported a 70% 12-month mortality rate in patients with HEV infection superimposed upon 
chronic liver disease and interestingly, HEV infection was associated with a higher mortality rate than 




GENOTYPE 3 AND 4 INFECTION 
Epidemiology – Figure 1 
HEV genotypes 3 and 4 are recognised to infect both humans and animals, in contrast with genotype 
1 and 2; pigs, deer and wild boar have all been identified as reservoirs of infection. Genotype 4 
infection mainly occurs in South-East Asia
39.41
. Genotype 3 HEV is the most prevalent genotype 
causing autochthonous (locally acquired) infection in developed countries
5
. Many seroprevalence 
studies have been undertaken in Europe, and the results have shown a high variability in 
seroprevalence rates. A recent meta-analysis identified 73 studies of HEV seroprevalence in Europe; 
estimates of seroprevalence ranged from 0.6% to 52.5%, with rates increasing with age but unrelated 
to gender
61
. In the United States, seroprevalence for anti-HEV is around 6%
62
, in the United Kingdom 
3-16%
63
 and in some regions of France up to 52%
64
. In England, the number of confirmed 
(symptomatic) cases of non-travel associated HEV infection has steadily increased over the past 14 
years, from 124 in 2003 to 958 in 2015
65
. However, a study from South-East England suggested that 
there are 80,000-100,000 infections per year in England, the majority of which are asymptomatic
66
. 
Autochthonous (locally acquired) HEV infection is not a benign condition, with mortality rates up to 




Interesting geographical variations in genotype 3 HEV infection have been observed in France where 
there is considerable variation in seroprevalence by region from 8-86%
68
; very high seroprevalence 
occurs in the southwest, southeast and northeast of the country
67,68,69
. The reason for this interesting 
observation is unclear, but contaminated foodstuffs in the food chain are likely to explain these 
geographical differences in part. There appears to be no correlation with potential transmission routes 
(e.g. location of pig farms). Although Scotland is a relatively low seroprevalence region, 
seroprevalence rates are also variable
70
. This geographical variation in HEV infection is worthy of 
further consideration and investigation. As in France the main pig-rearing/farming region is located in 
the North East of Scotland, in contrast to the area of peak HEV seroprevalence
70, 71
. In a study of 
patients with decompensated chronic liver disease from the United Kingdom and France, HEV was 
significantly more common in the French cohort compared with the United Kingdom cohort (7.9% 
versus 1.2% respectively; p = 0.003)
67
. Potential explanations for this include the quantum of 
circulating HEV in these respective regions, and the exposure to contaminated foodstuffs.  
 
Many countries have undertaken epidemiological studies of HEV seroprevalence in their respective 
blood donor populations (Table 2)
72-81
. Most countries report increasing incidence of HEV infection 
due to increased awareness of HEV, increased testing for the virus and a true increase in the 
numbers of new infections. Data from the Netherlands and Scotland suggests that this increase in 
incidence appears to be in younger patients, in contrast with previous observations that 
autochthonous HEV infection predominantly affects older (>60 years) males
70,82
. The results of a large 
survey of hepatitis E infection in French blood donors have recently been reported. Overall IgG 
seroprevalence was 22.4%, with an IgM seroprevalence of 1%
68
. IgM seroprevalence was highest in 
those patients living in the south of France and in those patients who self-reported consumption of 
pork liver sausage, pate and wild boar meat. The presence of HEV RNA was not reported upon in this 
large study, and there was no information given to suggest that any recipients of products from 
donors who were IgM positive developed active HEV infection. 
 
HEV genotype 4 is endemic in China, Japan and Indonesia, and recently cases have been reported in 
Western countries including Belgium, Germany and France
83,84,85
. There was an outbreak of genotype 
4 infection in Italy in 2011
86
. This outbreak was not directly linked to travel or infection by imported 
foods, raising the possibility of newly imported strains. All patients affected in this outbreak were male 
(mean age 59 years), and fatigue was the most frequently reported symptom.   
 
Importantly, the presence of HEV antibodies does not protect from further infection. A French group 
performed a longitudinal study of multi-transfused immunocompetent patients in France. In this study, 
one seropositive patient demonstrated an increase in IgG level and and HEV RNA reappearance, 






Genotype 3 and 4 infections are most commonly transmitted via contaminated foodstuffs. These 
foodstuffs include porcine liver and sausage products, shellfish, green vegetables and strawberries. In 
the United Kingdom, a questionnaire-based study identified that risks for autochthonous infection 
include consumption of processed pork products, including pork pies (OR 6.33), sausages (OR 7.59) 
and ham (OR 10.98)
88
. In a study of blood donors exposed to HEV infection in Southern France, 
foodstuffs associated with positive antibodies against HEV on multivariate analysis were uncooked 
pork liver sausages, offal and mussels
74
. To support this, HEV has been found to be highly prevalent 
amongst global pig populations.  For example, in Germany, 33% of wild boar and 50% of domestic 
pigs are seropositive for anti-HEV IgG
89,90
. HEV infection has been identified in more than 80% of 
some pig herds in the United States, Canada and in the United Kingdom (England)
91,92
, although 
Scottish herds have a lower seroprevalence of around 62%
93
.  In a more recent report on English and 
Northern Irish pigs, 93% of slaughter age animals were seropositive
91
.  
In the West of Scotland, 92% of tested wild caught mussels were PCR positive for HEV and 
consumption of undercooked/raw shellfish is another viable route of transmission
46
. Likewise, 
numerous studies have indicated HEV contamination of soft fruits, likely via exposure to contaminated 
water. In Quebec, Canada swine HEV was detected in strawberries (1.6% of samples tested)
94
. A 
separate study of the European berry fruit supply chain identified HEV in 2.6% of berries (raspberries) 
at point of sale
95
. A more recent study identified HEV in 5% of irrigation water samples from leafy 
green vegetable production chains
96
. 
In view of the seroprevalence in animal populations described above, it seems logical that HEV can 
be transmitted to humans via the consumption of contaminated foodstuffs.  Several studies have 
identified actual transmission of HEV to humans via the consumption of contaminated foodstuffs. One 
study investigated the role of figatellu (a traditional pig liver sausage eaten in France and commonly 
consumed raw): anti-HEV IgM or HEV RNA was positive in 7 out of 13 individuals who consumed raw 
figatellu, compared with 0 out of 5 individuals who did not eat figatellu
97
. Genetic links were identified 
between HEV RNA sequences recovered from supermarket figatellu and sequences recovered from 
patients eating the same product, providing firmer evidence that human HEV infection is associated 
with figatellu consumption. More recently, Lee reported upon a 55 year old man who was found to be 
HEV RNA positive at 22 months after liver transplantation
48
. The patient was Muslim, and therefore 
the potential route of food-borne transmission unclear. Phylogenetic analysis confirmed the patients 
HEV sequence to belong to camelid HEV; the patient owned a camel farm and subsequently 
confirmed regular consumption of camel meat and milk, making transmission via camel products the 
most likely source. In China, where mixed farming is common practice, a high prevalence of active 
HEV infection in cows was identified, and Huang demonstrated that HEV is excreted into milk that is 
produced by infected cows
98
. Therefore, HEV-contaminated cows milk is another potential zoonotic 
source; gavage of infected milk to rhesus macaques resulted in active HEV in infection as confirmed 
by HEV RNA in blood and faeces. However, in milk samples collected from dairy farms (i.e. not mixed 
farms) in Germany, no HEV RNA was detected
99
. The exact contribution of zoonotic HEV infection via 
dairy milk, and the potential contamination via mixed farming remains to be established. 
 
Transmission: via blood products  
Transmission of genotype 3 and 4 HEV by transfusion of blood products (including red cells, platelets 
and even pathogen-inactivated [Intercept treated] fresh frozen plasma) that are HEV-infected has also 
been reported in many Western (and some Asian) countries
66,100,101
. The incubation period for 
genotype 3 HEV infection in immunosuppressed patients with blood-borne HEV infection has been 
demonstrated to be 50-60 days, compared with less than 30 days for immunocompetent patients with 
genotype 1 infection
102




In Scotland, an increase in seroprevalence of genotype 3 infections has been observed; studies of the 
Scottish blood donor population in 2012 revealed 1 in 14,500 donors to be viraemic. More recent 





In southeast England, retrospective screening of 225,000 individual blood donations identified HEV 
RNA in 79 samples, equating with a prevalence of viraemia of 1 in 2848 donations
66
. Of all RNA-
positive samples undergoing genotyping, genotype 3 virus was identified in all cases. 79 donations 
from viraemic donors had been used to prepare 129 blood components, 62 of which had been 
transfused. Of the recipients of these components, 42% had evidence of infection, and 10 patients 
developed persistent infection. This study also suggested increased levels of circulating virus were 
associated with increased risk of infection. 
A study of Catalonia (Spain) blood donors reported a prevalence of anti-HEV IgG of 19.96% (Wantai 
assay), with a HEV RNA positivity rate of 0.03%, or one per 3333 donations
72
. Study of the blood 
donor population in southwestern France found that anti-HEV IgG was detectable in 52.5% of blood 
donors, with seroprevalence increasing with age and associated with rural residence
64
. Another group 
studied the presence of HEV RNA in manufacturing plasma pools from North America, Europe, the 
Middle East and Asia
104
. Asian pools were most frequently positive for HEV RNA and had higher viral 
loads, and there was no evidence of HEV in pools tested from the Middle East, presumably relating to 
the low rates of pork consumption in this region.  
 
Transmission: via solid organ transplantation 
Transmission of HEV infection can occur via liver transplantation and transplantation of non-hepatic 
grafts. Schlosser described a case of a 73 year old man in whom HEV transmission occurred after 
transplantation of a HEV-infected liver from a donor with occult HEV infection
105
. At the point of donor 
death, alanine aminotransferase was 4x upper limit of normal. The patient developed rapid graft 
cirrhosis and died from decompensated liver disease and septic shock. HEV was diagnosed at the 
time of hepatic decompensation; retrospective testing of a stored serum sample from 150 days post-
transplant was also positive for HEV RNA. Pre-mortal blood and liver tissue from the donor confirmed 
that the patients serum was HEV PCR negative, but HEV RNA was detected in high concentrations in 
the liver tissue of the donor. Sequence data from recipient serum and donor liver tissue were 
concordant, suggesting transmission of the virus via the transplanted liver.   More recently, there has 
been a report of HEV transmission via renal grafts
106
. The donor kidneys were transplanted into two 
separate recipients, and of note donor LFTs had been abnormal prior to transplantation. The first 
infected recipient presented at 9 months with deranged LFTS. Retrospective analysis detected 
negative HEV RNA until the day of transplantation, with positive RNA from the first month post 
transplant. The second recipient was identified after biomonitoring. Donor serum was positive for HEV 
RNA; genotype 3f was identified and this genotype was also identified in both recipients, providing 
evidence for transmission via non-hepatic solid organs. 
 
Clinical Features 
Immunocompetent individuals clear HEV promptly, usually within a few weeks. In these patients, HEV 
infection usually runs a mild course and is often asymptomatic. However, in the immunocompromised, 
HEV infection is often more difficult to clear, and about 60% of these patients go on to develop 
chronic HEV infection
6,7
. Chronic HEV infection may lead to complications such as liver cirrhosis.  
Clinical Features of Genotype 3 HEV infection 
In 2008 it was established that genotype 3 HEV infection may progress to chronic infection in patients 
who are immunocompromised (e.g. patients with HIV, leukaemia, high dose steroid therapy) and solid 
organ transplant recipients
6,107,108
. To date, chronic HEV infection has not been documented with 
genotype 1 or genotype 2 HEV infection. Chronic infection with genotype 4 HEV was reported in 
2015, and there has only been one case reported in the literature to date
109
.  
Chronic HEV infection (genotype 3) is generally defined as persisting serum HEV RNA and elevated 
liver enzymes 6 months after the acute phase
6
, although some units use a 3 month cut-off to define 
chronicity
110
. In Toulouse, France between January 2004 and December 2009, 50 cases of HEV 
infection in solid organ transplant patients were identified: 32 kidney transplant recipients, 3 kidney-
pancreas recipients and 15 liver transplant recipients. 45.7% of the kidney recipients in this cohort 
developed chronic HEV infection
111
. In a retrospective study analysing stored plasma from 2,919 HIV-
infected patients, 3 female patients were identified to have had HEV infection: 2 patients had acute 
HEV infection and 1 patient had chronic HEV infection for > 4 years (all infections genotype 3a)
112
. In 
addition to chronic HEV infection, reactivation of resolved infection has also been reported. One 
patient who had undergone stem cell transplant for leukaemia and was therefore immunosuppressed. 
Versluis described a patient who had initially cleared HEV infection, evidenced by 53 days with an 
undetectable HEV RNA
113
. At the time of allogeneic stem cell transplantation, HEV RNA was 
detectable, although viral load was low. Viral reactivation post stem cell transplant was based upon 
rising HEV RNA levels and identical HEV-ORF1b sequences. This patient later cleared infection with 
a reduction in immunosuppression and ribavirin therapy. 
In organ transplant recipients, chronic HEV genotype 3 infection may lead to cirrhosis and liver failure 
within 1-2 years
7
. This may in turn lead to a requirement for re-transplantation. In transplant patients, 
anti-HEV IgM and IgG may be negative and therefore RNA testing by polymerase chain reaction 
(PCR) must be employed. Pas demonstrated that anti-HEV IgM could only be detected in 7/16 
immunocompromised patients compared with 18/18 immunocompetent patients in the acute phase of 
infection, suggesting a delayed immune response and abnormal IgM antibody kinetics in the 
immunocompromised group
114
.   
  
A UK/French study also looked at the role of HEV infection in patients with decompensated chronic 
liver disease
67
. Acute HEV infection (genotype 3) was identified in a minority (3.2%) of patients with 
decompensated chronic liver disease, and there were no differences in mortality between patients 
with and without HEV infection. It is likely that HEV genotype 3 infection in patients with chronic liver 
disease confers an adverse prognosis (similar to that of other insults causing decompensation), but 
this effect is less than that seen with HEV genotype 1 infection as seen in a cohort of Indian 
patients
60
. The role of the genotype of HEV in acute on chronic liver failure/decompensated chronic 
liver disease and its effect on patient outcome is therefore less certain, and requires further 
investigation.  
 
EXTRAHEPATIC MANIFESTATIONS OF HEV 
HEV infection may also present with extrahepatic manifestations. In vitro data has identified that HEV 
can replicate in non-liver cells including human intestine
115
.  
Neurological manifestations have been reported in HEV genotypes 1 and 3 infection. HEV RNA has 
been found in the cerebrospinal fluid of patients with neurological symptoms during HEV infection
116
. 
A Dutch study reported up to 5% of patients with Guillain-Barre syndrome had associated acute HEV 
infection
117
. Other reported neurological disorders include neuralgic amyotrophy, transverse myelitis 
and cranial nerve palsies. Other recognised extrahepatic manifestations of HEV infection include 
renal impairment with cryoglobulinaemia, pancreatitis and haematological abnormalities. HEV 
infection can cause severe kidney disease and should be considered in cases of unexplained 
glomerular disease. Arthritis and pancreatitis have also been reported.  
 
DIAGNOSIS OF HEV INFECTION 
Clinically, cases of HEV infection are indistinguishable from other causes of acute viral hepatitis. HEV 
infection can be diagnosed either indirectly by the demonstration of anti-HEV antibodies or directly by 
detecting HEV RNA using a quantitative reverse transcription polymerase chain reaction in serum, 
plasma or stool samples. During acute HEV infection, anti-HEV IgM becomes detectable in the days 
prior to the onset of symptomatic illness and becomes undetectable again at 4-6 months. Anti-HEV 
IgG becomes detectable soon after the presence of anti-HEV IgM, and persists for many years, even 
life-long in some patients. In 95% of patients, anti-HEV IgG is detectable at time of first clinical 
presentation
118
. Nucleic acid testing is essential to exclude HEV infection in the immunosuppressed 
population in view of the poor antibody response in such individuals. 
 
There is currently no consensus across laboratories for HEV testing, and the sensitivity and specificity 
of HEV assays vary widely. This may at least in part account for the differences in reported rates of 
anti-HEV antibody in various populations. For example, within one country (UK), the prevalence of 
anti-HEV antibody in the blood donor population was 3.6% as detected by one assay, compared with 
16.2% with the use of an alternative
63
. In the recent meta-analysis of HEV seroprevalence in Europe 
by Hartl, seroprevalence again varied depending upon the assay used, with the Wantai assay 
reporting significantly higher seroprevalence rates across all cohorts tested
61
. As a result, it can be 
difficult and unreliable to compare data from different populations obtained by different laboratory 
methods. Several serological methods are available for diagnosis of HEV, including enzyme 
immunoassay and immunochromatography. Anti-HEV IgM can be difficult to detect, which may hinder 
the diagnosis of acute HEV infection, Abravanel reported upon the performance of a HEV IgM rapid 
test from Wantai in detecting anti-HEV IgM in both immunocompetent and immunocompromised 
patients
119
. The rapid Wantai assay is a relatively new, immunochromatographic assay which can 
rapidly detect anti-HEV IgM. Abravanel identified that the sensitivity of this assay was higher in 
immunocompetent patients (sensitivity 97.7%; 95% CI 87.9-99.9%) compared with the 
immunocompromised (sensitivity 85%; 95% CI 70.2-94.3%). 
In an attempt to harmonise HEV PCR techniques and standards, the World Health Organisation 
initiated the production of international standards for anti-HEV IgG and HEV RNA
120
. This work 
involved 23 laboratories from 10 countries; in summary the World Health Organisation established a 
genotype 3a HEV strain as the International Standard strain for HEV RNA, with an assigned a unitage 
of 250,000 IU/mL. With regards to serology, there are no World Health Organisation reference 
materials available at present but this work is in progress. 
Serum anti-HEV IgM and IgG may be negative in the presence of active HEV infection, and this may 
be as a result of the sensitivity of assays used, and/or the immunocompetence status of the patient. 
There have been reports of false positive results from anti-HEV IgM assays in cases of Epstein-Barr 
virus and cytomegalovirus infection
121
. Therefore, HEV RNA PCR is the favoured diagnostic test, 
particularly in the immunocompromised. If the patient has undergone liver biopsy for investigation of 
acute or chronic hepatitis, histology commonly demonstrates a non-specific hepatitis which may easily 
be attributed to an alternative cause, and the diagnosis must be confirmed with HEV Ag 
immunohistochemistry. However, the availability of this technique is limited. 
 
DIAGNOSTIC MIMICRY 
As HEV infection (both acute and chronic) is clinically indistinguishable from other causes of hepatitis, 
it is likely that HEV infection is under-diagnosed. The relevance of autochthonous HEV infection is 
only recently recognised, and it is likely that patients who have presented with severe acute liver 
injury/acute liver failure due to HEV in the past have been mislabelled as having an alternative 
diagnosis. As such, several centres have retrospectively analysed stored sera from patients with 
indeterminate acute liver failure (i.e. non A to E hepatitis, seronegative hepatitis) for presence of HEV. 
One German group retrospectively analysed stored sera from patients with ‘indeterminate acute liver 
failure’ for anti-HEV IgM, IgG and HEV RNA
122
. 10% of samples tested positive for HEV RNA and had 
clinical findings which would support the diagnosis of acute HEV infection. In Scotland, 80 patients 
with severe acute liver injury were tested for serological markers of HEV infection
123
. 3 patients tested 
positive for anti-HEV IgG, anti-HEV IgM and HEV RNA. 1 further patient tested anti-HEV IgG and IgM 
positive, but HEV RNA negative. The patient with negative HEV RNA testing had been initially 
diagnosed as having acute liver failure secondary to a paracetamol overdose. Of the other patients, 
one was initially diagnosed as having a drug induced liver injury, another had travel-acquired HEV 
infection and the remainder was found to have liver cirrhosis on further investigation, presenting with 
decompensated disease secondary to HEV.  In addition, patients previously having been labelled as 
having drug induced liver injury are increasingly recognised to in fact have had acute HEV infection. 
In a United Kingdom study of patients with drug induced liver injury, on retrospective testing 13% 
were found to have autochthonous HEV infection
124
. Smaller numbers have been reported from the 
United States- 3% of patients with suspected drug induced liver injury retrospectively tested positive 
for anti-HEV IgM
125
.  In patients undergoing allogeneic haematopoietic stem cell transplant, graft 
versus host disease may present with clinical features similar to HEV infection. In one study of stem 
cell transplant recipients, 2.4% of 328 patients developed HEV infection, in which the pattern of liver 
function test abnormality was indistinguishable from that of graft-versus-host disease
113
. This is 
clearly an important clinical distinction to make as the two conditions are treated entirely differently in 
terms of adjustments of immunosuppression.  
 
HEV REINFECTION 
Re-infection with HEV is reported, and can be identified by a rapid increase in anti-HEV IgG levels, 
with HEV RNA becoming detectable. Abravanel followed a cohort of 263 solid organ transplant 
recipients for one year; in addition to three cases of de novo HEV infection, there were 3 cases of 
HEV reinfection
126
. Patients who tested positive for anti-HEV IgG, with or without detection of anti-
HEV IgM at transplantation, and tested positive for HEV RNA during follow up were considered to 
have become reinfected. Reinfection with HEV can lead to a chronic infection and further studies are 
required to evaluate the clinical importance of HEV reinfection in immunosuppressed patients.  
Previously, reinfection or chronic infection was associated only with immunosuppressed patients and 
not the healthy donor population. However, Baylis recently reported HEV re-infection in a small 
percentage of plasma donors, as suggested by anti-HEV IgG with high avidity and high viral loads, in 
the absence of anti-HEV IgM
127
. Schemmerer also reported reinfection in 8.8% of individual patient 
courses
128
; the preexisting anti-HEV IgG concentration was <7 WU mL
-1
, and one patient had a 
serologic profile indicating 4 consecutive reinfections in intervals of 1.2-3.4 years.   
 
TREATMENT OF HEV INFECTION 
Liver transplantation for fulminant hepatitis 
It is rare for patients with HEV induced acute liver failure to require emergency liver transplantation. 
The United States Acute Liver Failure Study Group reported upon 681 patients with acute liver 
injury/failure who were tested for anti-HEV IgM and IgG levels
129
; those with detectable IgM levels 
underwent HEV RNA testing. One patient who was initially found to have a positive anti-HEV IgM 
proceeded to emergency liver transplantation. However, in this case the diagnosis of HEV and its 
potential causative role in acute liver failure was not clear cut; repeat samples for anti-HEV IgM were 
negative, and although initial anti-HEV IgG was positive, repeat serum samples were negative. HEV 
RNA was never detected. Following further investigation, it was felt likely that the cause of the acute 
liver failure and requirement for transplantation was in fact inadvertent paracetamol overdose. There 
are no other reports of emergency liver transplantation for acute HEV infection in the literature.  
 
Medical Therapy 
Following the identification of chronic HEV infection, there were case reports of successful viral 
clearance following ribavirin and/or pegylated interferon treatment. Both ribavirin and pegylated 
interferon inhibit HEV replication in vitro. However, pegylated interferon is contraindicated in kidney 
transplant recipients due to an appreciable risk of acute rejection and ribavirin has subsequently 
become the first line medical treatment for both acute (if required) and chronic HEV infection (Table 
3)
111, 130-135
. Gerolami first reported upon the use of ribavirin in the treatment of acute HEV genotype 3 
infection in 2011
136
; the patient was immunocompetent and was treated for 3 weeks, with 
normalisation of alanine aminotransferase and a fall in detectable HEV RNA levels. Treatment is most 
commonly started if HEV RNA remains detectable at 3 months, however this remains an off licence 
use.  Ribavirin has also been used to treat acute HEV genotype 1 infection: Pischke described 
treatment of a patient with acute HEV genotype 1e infection (acquired in Eritrea) with ribavirin for 6 
weeks and the patient obtained SVR
133
. The effect of ribavirin treatment on HEV genotype 1 infection 
has recently been studied using human liver chimeric mice. Ribavirin treatment led to a statistically 
significant decrease in viraemia after 6 weeks of treatment, together with a sharp decline in ORF2 and 




Worryingly, cases of ribavirin resistance and treatment failure have been reported, often related to a 
reduction in ribavirin dose because of side effects (e.g. anaemia). In one case series of patients 
undergoing treatment of HEV infection, ribavirin-induced anaemia necessitated dose reduction in 
29%; the use of erythropoietin in 54% and blood transfusions in 12%
130
. The G1634R mutation in the 
HEV ORF1 protein has also been associated with treatment failure; one study demonstrated that in 
patients with ribavirin treatment failure, all patients had this mutation
131
. The G1634R mutation 
increases the replicative capacity of HEV in the human liver, and thereby reduces the efficacy of 
ribavirin.  
Recently, ribavirin has been reported as mutagenic for the HEV genome during treatment of chronic 
infection, with an increasing number of variants being identified and mutations in all open reading 
frames of the genome
137
. In addition to the previously identified G1634R mutation, K1838N, D1384G, 
V1479I and Y1587F mutations are selected in non-responders to ribavirin therapy. In essence, 
ribavirin exerts mutagenic pressure on the viral genome and whilst this may result in viral clearance, it 
may also lead to the selection of resistant variants in those patients who do not respond.  
Debing described a patient with chronic HEV infection, who experienced treatment failure with 
ribavirin, with a resistant phenotype
138
. In this case, although HEV RNA was undetectable after 10 
weeks of treatment, eight weeks after treatment cessation the patient had viral relapse. Ribavirin was 
subsequently restarted and at 58 weeks post re-introduction of ribavirin, HEV RNA was still 
detectable. Next generation sequencing was performed to identify mutations associated with ribavirin 
resistance: resistance was associated with Y1320H, K1383N and G1634R mutations in the viral 
polymerase, in addition to an insertion in the hypervariable region. Subsequent in vitro studies 
identified that Y1320H and G1634R mutations have replication-increasing roles, whereas the K1383N 
mutation suppressed viral replication and in fact increased the in vitro sensitivity to ribavirin. Further 
deep sequencing of hepatitis E genomes demonstrated that ribavirin is mutagenic to viral replication 
in vitro and in vivo.     
 
Treatment of chronic HEV infection in transplant recipients (and other immunocompromised patients) 
Solid organ transplant recipients represent a unique therapeutic challenge in the management of HEV 
infection. Commonly used immunosuppressive agents are now known to affect the in vitro replication 
of HEV. mTOR (mammalian target of rapamaycin) inhibitors (e.g. everolimus) promote in vitro HEV 
replication via mTOR inhibition
139
. The calcineurin inhibitors (tacrolimus, ciclosporin A) have also been 
shown to have a pro-proliferative effect, in contrast to mycophenolate mofetil which inhibits HEV 
replication in vitro
140
.   
In transplant recipients, the initial treatment approach should be to reduce immunosuppression if this 
is feasible. Reduction in immunosuppression by approximately 30% results in clearance of chronic 
HEV infection in around 30% of this patient cohort
7
. For patients who cannot reduce 
immunosuppression or who fail to clear the virus despite a reduction in immunosuppression, ribavirin 
monotherapy is the treatment of choice for the majority of patients (Table 3)
111, 130-135
. Sustained viral 
response is the aim of therapy, defined as an undetectable serum HEV RNA level at least 6 months 
after treatment cessation. There is no definitive guidance as to the ideal treatment duration and 
dosage; there are reports of treatment courses lasting 1 month to 9 months, with the majority of units 
who have reported their experience favouring a 3-month course. Initial starting doses of ribavirin 
range from 600-1000mg. Factors associated with achieving a sustained viral response include a 
higher lymphocyte count when ribavirin therapy was initiated
130
. Kamar reported that in 59 solid organ 
transplant recipients who were treated with a median of 9 months of ribavirin for chronic HEV 
infection, sustained viral response was obtained in 78%. Importantly, in those patients who had 
recurrence and completed a second, prolonged course of ribavirin, sustained viral response could be 




Other antiviral drugs have been investigated in the treatment of HEV in view of potential treatment 
failure with ribavirin. The role of sofosbuvir, a directly acting antiviral which is the oral prodrug of a 
nucleotide hepatitis C virus-RNA-dependent polymerase inhibitor, has been studied. Dao Thi 
demonstrated that sofosbuvir efficiently inhibited HEV genotype 3 replication in vitro
141
. Furthermore, 
this group were able to demonstrate an additive effect when combined with ribavirin. The authors of 
this paper did recognise that the anti-HEV property of sofosbuvir is less marked than its anti-hepatitis 
C property, and clinical studies were required to confirm the efficacy of sofosbuvir in treating human 
HEV infection, particularly in those who have failed to clear HEV with ribavirin therapy alone. 
Following this, Donnelly described a patient with chronic hepatitis C and HEV infection post-
transplant, who was treated with sofosbuvir and daclatasvir (predominantly for hepatitis C infection 
and in view of previous ribavirin intolerance) and observed the effects of this treatment on HEV RNA 
and HEV-specific T-cell responses
142
. Despite the previous report of the inhibition of HEV replication 
in vitro with sofosbuvir, in this human study, no effect was seen on either HEV RNA levels or HEV-
specific T-cell responses. Brown later characterised host T-cell responses against HEV and similarly 
demonstrated that in organ transplant recipients, anti-HEV T-cell responses were reduced in breadth 
and magnitude
143
. Another group studied the effect of sofosbuvir combined with ribavirin against HEV 
genotype 3 infection in a human patient: sofosbuvir at a standard dose had some antiviral activity 
against HEV (as evidenced by a decline in HEV RNA levels) but was not potent enough to induce 
viral clearance
144
. The authors suggest that higher doses of sofosbuvir may be required to completely 
suppress viral replication; this would be an expensive approach to HEV treatment, and the potential 
side effects with this dose of therapy are unknown. 
 
An American study analysed the prevalence and clinical consequences of HEV infection in patients 
who had previously undergone liver transplantation for chronic hepatitis C infection
145
. 42% of patients 
had detectable anti-HEV IgG at some point from baseline (pre-transplantation) until the end of the five 
year follow up period; 5 patients were anti-HEV IgM positive pre-transplant, one patient demonstrated 
IgM seroconversion post-transplant and eight patients had IgG seroconversion post-transplant. Of 
those patients seroconverting post-transplant, eight had been treated for hepatitis C recurrence 
before or at the time of seroconversion. The authors felt that post-transplant treatment of hepatitis C 
recurrence with ribavirin/PEG-IFN may have afforded a degree of protection against HEV, and 
warned that with increasing use of new directly acting antiviral agents, the prevalence of chronic HEV 
infection in this population may in fact begin to increase.  
 
PREVENTION OF HEV INFECTION 
GENOTYPE 1 and 2 INFECTION 
HEV is becoming a real global public health problem, and a focus on prevention of infection must be 
considered. Globally, basic sanitation must remain the first line of defence against HEV infection. 
However, it is recognised that during outbreaks, basic sanitation and simple health interventions do 
not adequately prevent additional infections. Therefore, a vaccine against HEV is highly desirable, 
particularly for residents living in highly endemic areas and for those at high risk of developing 
complications e.g. the immunosuppressed. As all HEV genotypes belong to the same serotype, it is 
thought that one HEV vaccine should provide protection against all HEV genotypes. Due to difficulties 
in culturing HEV, it has not been feasible to produce enough virus for vaccine production for either live 
attenuated or inactivated vaccine against this virus
146
. Vaccine development therefore relies on 
preparation of recombinant HEV antigens or DNA. At least 11 experimental vaccines have been 
evaluated in non-human primates
146
. Two recombinant HEV vaccines (developed from genotype 1) 
have been shown to have short term efficacy in humans
147, 148
.  A genotype I HEV recombinant 
protein (rHEV) vaccine had been trialled in volunteers from the Nepalese army, however this vaccine 
has been removed from the development pipeline
146, 147
. 
The long term efficacy of the licensed Xiamen Innovax Biotech anti-HEV vaccine (Hecolin) has 
recently been studied in adult patients in China
148
. Patients were randomly assigned to receive either 
three doses of the HEV vaccine, or a hepatitis B vaccine. In the HEV vaccine group, 0.3 cases per 
10,000 person-years were identified, compared with 2.1 cases per 10,000 person-years in the 
hepatitis B vaccine (control) group, affording a vaccine efficacy of 86.6%. On follow up, the HEV 
vaccine induced antibodies against HEV and provided protection against HEV for up to 4.5 years, and 
importantly, no safety concerns relating to the use of this vaccine were reported. Although there were 
some clinical issues relating to this study, for example the potential for missed cases of HEV despite 
vaccination due to the lack of regular follow up assessments, the promise of a safe and effective anti-
HEV vaccine seems achievable in the near future. The WHO SAGE working group on Hepatitis E has 
identified and recognised the need for reviewing the existing data on the safety, efficacy and cost-
effectiveness of the licensed hepatitis E vaccine and identifying the potential indications and uses for 




GENOTYPE 3 and 4 INFECTION 
In the Western world, as transmission is predominantly via undercooked foodstuffs there must be 
education on adequate cooking to minimise risk of transmission via the food chain:  for example, the 





. With regards to prevention of transmission via contaminated blood products, there is no 
evidence at present to support the need for HEV negative blood components for pregnant women. At 
present in England, and more recently in Scotland, NHS Blood and Transplant recommend that HEV 
negative blood should be used in patients who have undergone allogeneic stem cell transplant or 
solid organ transplant
151
. The UK Advisory Committee on the Safety of Blood, Tissues and Organs 





NEW APPROACHES TO TREATMENT, FUTURE WORK AND RECOMMENDATIONS 
Firstly, standardisation of diagnostic assays is key to ensure as many cases of HEV infection are 
detected as possible. Work is currently underway to develop World Health Organisation reference 
materials for HEV serology, which will be available in due course as a worldwide resource. Dedicated 
studies are required to clarify the optimal dose and treatment duration of ribavirin therapy. With 
regards to the development of new treatment strategies, targeting viral polymerase may provide a 
new approach to therapy, and the recent availability of cell culture models/systems will allow new 
opportunities for the study of HEV biology and the development of targeted therapeutic and/or 
prophylactic strategies. Deep sequencing technology may prove invaluable in identifying patients at 
risk of treatment failure with ribavirin; its use may become important in a ‘personalised medicine’ 
approach to the treatment of chronic HEV infection. Future work should focus on increasing 
awareness of HEV infection in the developed world, emphasising the need for clinicians to have a low 
threshold for HEV testing, particularly in immunosuppressed patients. Patients at potential risk of 
chronic HEV infection must also be educated and made aware of modes of transmission of infection 
and given advice regarding prevention of infection e.g. routine advice should be given to stem cell and 
solid organ transplant recipients regarding risk of eating under or poorly cooked pork or pork products. 
Other attempts to reduce the risk of transmission of infection and infection in high risk patients could 
include the global use of HEV negative blood in immunosuppressed patients, including the organ and 
stem cell transplant population. Future clinical trials could include trials of alternative 
immunosuppression regimens in the transplant population: as described above the role of certain 
therapies in the development of HEV infection is now recognised, and trials of alternative treatment 
options for those patients who have failed ribavirin therapy, and/or have the presence of the G1634R 
mutation are required. Clinicians must be vigilant to the possibility of HEV infection, particularly in 
elderly men, solid organ transplant recipients and the immunosuppressed, and understand how to 
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Figure 1. Worldwide endemicity for HEV infection 
Figure 2. Organisation of the HEV genome.  
A schematic diagram of the genomic and subgenomic organisation of the HEV genome. The open 
reading frames are shown as boxes and labelled. The non-coding features are labeled and the 
putative domains of ORF1 are also shown. In genotype 1 strains, a putative ORF4 has been identified 
and falls within the ORF1 coding region. Modified from Cao & Meng 2012. CRE, cis-reactive element; 
Hel, Helicase; HVR, hypervariable region; JR junction region; MT, methyltransferase; NCR, non-
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 Table 1. Characteristics of HEV infection according to genotype. 
CHARACTERISTIC GENOTYPE I+2 GENOTYPE 3+4 
Species specificity Restricted to humans Zoonotic 
Geography Developing world Developing and developed 
world 
Pattern of spread Epidemic and sporadic Sporadic 
Mode of transmission Faecal-oral spread 
(contaminated water) 
Contaminated food products 
(e.g. pork) 
Blood products 
Solid organ transplantation 
Age distribution More common amongst 
adolescents and young adults 
More common amongst older 
adults 
Sex distribution Affects males and females 
equally 
More common in males 
Chronic infection Not recognised Now recognised, common in 
immunosuppressed patients 
Therapy None Ribavirin, peginterferon 
Mortality High amongst pregnant women Higher amongst older adults 
 
Table 2.  HEV seroprevalence in screened blood donor populations




HEV RNA POSITIVITY RATE 
Spain, 2014
72 
19.96% (Wantai assay) 
10.72% (Mikrogen assay) 
1 per 3333 donations 
US, 2015
73 
9.5% 1 per 9500 donations 
Southern France, 2011
74 










13.55% (Wantai assay) 1 per 8416 donations 
Sweden, 2012
78 
NA 1 per 7986 donations 
Germany, 2012
79 
5.94% (Mikrogen assay) 1 per 1240 donations 
England, 2010
63 
16.2% (Wantai assay) 
3.6% (MP assay) 
Data not available 
England, 2014
66 
 29% (Wantai assay) 1 per 2848 donations 
Holland, 2013
80 
27% (Wantai assay) 1 per 2671 donations 
Scotland, 2013
81 











Table 3.  Treatment of chronic HEV infection with ribavirin in immunosuppressed patients 
STUDY POPULATION TREATMENT 
REGIMEN 
OUTCOME 





Dose: median 800mg 
per day 
Duration: 3 months 
SVR 67% 
Kamar N et al 
2014
130 
Solid organ (all) 
transplant recipients 
with genotype 3 
infection, France  
Dose: median 600mg 
per day 
Duration: median 3 
months 
SVR in 78% 
Debing Y et al 
2014
131 
Solid organ (all) 
transplant recipients 
with genotype 3 
infection, Germany 
Dose: initial daily dose 
600-1000mg 
Duration: not specified 
Treatment successful in 
87% 







Dose: 400-600mg per 
day 
Duration: 3 months 
RNA negative at 2 and 3 
months post treatment 
cessation 
Pischke S et al 
2013
133 
Solid organ (all) 
transplant recipients  
Dose: initial daily dose 
600-1000mg  
Duration:5 months 
SVR in 81% 





Dose: median 800mg 
per day 
Duration: median 3 
months 
RNA undetectable after 
30 days in all treated 
patients 





Dose:initial daily dose 
400-800mg 
Duration: 3 months 
SVR in 75% 
 















Table 4. Recommendations on the use of HEV-screened blood components
152 
PATIENT GROUP RECOMMENDATION REGARDING BLOOD 
COMPONENTS 
SOLID ORGAN TRANSPLANTATION(SOT)  
All HEV-screened components should be given to all 
SOT recipients taking immunosuppressant 
medication  
Potential SOT recipients From 3 months prior to date of elective SOT 
potential recipients should only receive screened 
components. Patients likely to be transplanted 
within 3 months and currently not receiving 
immunosuppression should be given HEV 
screened components.  
Any patient receiving immunosuppression before 
SOT 
Should receive screened components only 
Extra corporeal procedures Screened components should be used for extra 
corporeal circulatory support for patients 
undergoing SOT, and for SOT patients receiving 
immunosuppression 
HAEMATOPOIETIC STEM CELL 
TRANSPLANTATION (HSCT) 
 
Allogeneic HSCT Screened components should be given to 
potential allogeneic HSCT recipients from 3 
months prior to date of planned HSCT until 6 
months following HSCT, or for as long as patient 
is immunosuppressed 
Autologous HSCT No convincing evidence at present to support 
recipients receiving screened components.  
 
 
Table 5. Clinicians guide to testing for and treatment of hepatitis E 
Question? Take home message 
Which patients should be tested for HEV?  ALT ≥ 300 IU/L (all patients) 
 ALT/ALP ratio ≥ 2 (all patients) 
 Suspected drug induced liver injury 
 Severe acute liver injury (all patients) 
How should we test for HEV?  Anti-HEV IgM should be the initial 
serological test of choice 
 If IgM positive, HEV RNA by PCR in 
serum or stool should be used to 
confirm active infection 
 HEV RNA by PCR should be the initial 
test of choice in immunosuppressed 
patients 
How long should I treat HEV infection with 
ribavirin for? 
 For chronic HEV infection, the initial 
course of ribavirin therapy should be for 
3 months 
 If the patient is immunosuppressed e.g. 
is a solid organ transplant recipient, 
consider a trial of a reduction in 
immunosuppression in the first instance 
What should I do in the case of ribavirin 
non-response? 
 Extend course of ribavirin therapy for a 
further 3 months 
 If still no response, continue ribavirin for 
further 6 months 
 Consider trial of pegylated interferon for 
3 months (not in renal transplant 
recipients) 
 
 
  
 
